Ratings by Citi (Peter Verdult)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/13/2024 | Eli Lilly | LLY | New Coverage | Buy (N/A) |
920.89 (1133.00) |
23.03% | Details | |
| 1/12/2023 | Sanofi-Aventis | SNY | New Coverage | Buy (N/A) |
48.82 (44.25) |
-9.36% | Details | |
| 12/20/2022 | Genmab A/S | GMAB | Downgrade | Neutral (Buy) |
43.04 (25.08) |
-41.73% | Details | |
| 1/27/2022 | Galapagos NV | GLPG | Upgrade | Buy (Neutral) |
53.15 (27.73) |
-47.83% | Details | |
| 1/7/2022 | Evotec | EVO | New Coverage | Neutral (N/A) |
22.07 (2.72) |
-87.68% | Details | |
| 9/20/2018 | Bayer AG | BAYRY | Upgrade | Buy (Neutral) |
21.46 (10.44) |
-51.35% | Details | |
| 8/21/2018 | Sanofi-Aventis | SNY | Maintain | Buy (N/A) |
|
Details | ||
| 8/21/2018 | Merck KGaA (ADR) | MKKGY | Maintain | Buy (N/A) |
|
Details | ||
| 8/13/2018 | Bayer AG | BAYRY | Downgrade | Neutral (Buy) |
27.60 (21.46) |
-22.25% | Details |
